Candriam Eq. L Biotechnology V $
Rating and Score (On 30/06/2026)
Rating
FIDA
Rating
ESG
FIDA Category
***Some functions are not available in this version.***
Register for free to unlock functions
Static data
Name | Candriam Eq. L Biotechnology V $ |
Typology | Funds and Sicav |
ISIN Code | LU0317020203 |
Sicav | Candriam Equities L Sicav |
Registration country | - |
Country authorised for sale | |
Asset manager | |
Address | Serenity Bloc B 19-21, route d'Arlon L-8009 Strassen |
Phone | |
Web site | |
FIDA Category | |
Assogestioni category | |
EFAMA Category | Equity Health Care |
Priips | Yes |
Official benchmark | 100.00% - NASDAQ Biotech Index |
Start Date placement | 01/03/2016 |
Search by currency | Usd - us dollar |
Quotation currency | Usd - us dollar |
Status | Active |
Distribution policy | No |
Total asset value at 30/07/2026 | 114.08 mln USD |
Documentation |
Quotation evolution (From 02/08/2023 On 31/07/2026)
3,324.98
80.45
%
31/07/2026
Loading data
Quote
Quotation currency | Usd - us dollar |
Quotation frequency | Daily |
Last quotation | $3,324.98 (31/07/2026) |
% change | |
Last Price in Euro | €2,895.06 |
Investment Objective
Principal assets traded:Equities of companies active in biotechnology whose registered offices and/or principal activities are throughout the world.Investment strategy:The fund seeks to achieve capital growth by investing in the principal assets traded and to outperform the benchmark.The management team makes discretionary investment choices based on economic/financial analyses.There are two strands in the selection of companies: a clinical analysis and a fundamental analysis.The clinical analysis aims to assess the quality of the available clinical data and to use only companies found to be convincing in this respect.The fundamental analysis selects the best companies according to five criteria: quality of management, growth potential, competitive advantage, value creation and indebtedness.The fund promotes, among other characteristics, environmental and/or social characteristics but does not have sustainable investment as its objective. The analysis of ESG aspects (environment, social, governance) is included in the selection, analysis and global evaluation of companies. The Fund also aims to exclude investments in companies which do not respect certain recognised international standards and principles, or which are significantly exposed to certain controversial activities. Under certain conditions, the analysis and selection process may also be accompanied by active involvement, in particular dialogue with companies and voting as the shareholder at AGMs. For more information, please see the management company's website and/or the prospectus.The fund may make use of derivative products for both investment and hedging purposes (to protect against future unfavourable financial events).Benchmark: NASDAQ Biotechnology Index (Net Return). The fund is managed actively and the investment approach implies a reference to a benchmark (the index).Benchmark definition:The index measures the performance of NASDAQ-listed companies from the biotechnology and pharmaceuticals sect |
Tax system
PIR compliant | No |
PEA compliant | No |
PEA-PME compliant | No |
Company registry
Asset manager | |
Phone | |
Web site | |
Address | Serenity Bloc B 19-21, route d'Arlon L-8009 Strassen |
The data and information covered by the Service are for the exclusive internal use of the User and may neither be transferred to third parties, nor circulated, disclosed or allowed to be disclosed, nor used on external information systems, without the written consent of FIDA and, when necessary, of the information sources.
